Affordable Access

Publisher Website

Secondary prevention of stroke in elderly people in Poland—Results of PolSenior study

Authors
Journal
Neurologia i Neurochirurgia Polska
0028-3843
Publisher
Elsevier
Volume
48
Issue
2
Identifiers
DOI: 10.1016/j.pjnns.2013.11.001
Keywords
  • Stroke
  • The Elderly
  • Secondary Prevention
  • Oral Anticoagulant Drugs
  • Antiplatelet Drugs
  • Acetylsalicylic Acid
Disciplines
  • Education
  • Medicine

Abstract

Abstract Background and purpose The purpose of the study was to evaluate the frequency of use of oral antiplatelet (OAP) and anticoagulant (OAC) drugs as secondary stroke prevention among older people in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods The study group consisted of 426 subjects with a history of a previous stroke (mean age of 81.5±8.2 years), participants of multicentre, population-based PolSenior study. Results Among the study group, 261 people (61.3%) used at least one drug as a secondary prevention. OAPs were regularly used by 237 people (55.6%), and OACs—by 25 people (5.9%). The most often used drug was acetylsalicylic acid. Ticlopidine was more frequently used than clopidogrel, and acenocoumarol was used more often than warfarin. Among all of the concomitant cardiovascular risk factors, congestive heart failure was mostly associated with OAP treatment, and a history of atrial fibrillation—with OAC treatment. Use of drugs did not depend on age, sex, place of residence (rural or urban), level of education and personal income, but it was associated with the region where the respondents lived. Conclusions Secondary cardiovascular preventive therapy in Poland is used too rarely in older people after stroke, and it especially concerns anticoagulant therapy in those with a history of atrial fibrillation. Structured educational programmes should be developed in Poland to improve usage of secondary preventive therapy in the elderly.

There are no comments yet on this publication. Be the first to share your thoughts.